Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

At the annual American Urological Association (AUA) meeting this week in Washington DC, Dr Matthew Smith from Mass General Hospital presented updated data from the phase III 147 trial comparing denosumab to placebo in managing skeletal related events (SREs) and bone metastases-free survival.   Skeletal complications are a major cause of prostate cancer morbidity.

The results were somewhat controversial, however, because while surrogate measures such as delaying time to SREs clearly show a benefit in favour of denosumab, no difference in overall survival was seen over placebo.

To find out whether these measures are clinically meaningful or not, I chatted with Dr Neal Shore, a urologist who is the Medical Director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina as part of the ongoing Making a Difference series of interviews.

One Response to “Managing bone metastases with denosumab in prostate cancer: an interview with Dr Neal Shore”

Comments are closed.

error:
error: Content is protected !!